[Subablative gentamycin therapy in Menière's disease].
We have treated 20 patients suffering from unilateral Morbus Meniere (2 x 12 mg gentamicin for 7 days). These patients were controlled for 24 months. In 95% we regarded a complete or substantial control of definitive spells ("American Committee on Hearing and Equilibrium guidelines for reporting treatment results in Meniere's disease", Otolaryngol. Head and Neck Surg. 10/19-85). Only 1 patient with pretherapeutic equal caloric response showed a post-therapeutic destroyed vestibular apparatus on the treated ear. In the other 7 patients (35%), who had a loss of vestibular function after therapy, there was an already pretherapeutic more or less noticeable caloric hypoexcitability. It is possible to induce an only subablative damage with a clinical success in 95%.
Hoffmann
F
F
Universitäts-HNO-Klinik Freiburg.
Beck
C
C
Beck
C
C
Stratulat
S
S
D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D002150:Caloric Tests; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004432:Ear, Middle / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D005839:Gentamicins / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged; D004856:Postural Balance / Q000187:drug effects; D014722:Vestibule, Labyrinth / Q000187:drug effects
D005839:Gentamicins
Subablative Gentamicintherapie bei M. Menière.